PT - JOURNAL ARTICLE AU - Zhen, Wei AU - Manji, Ryhana AU - Smith, Elizabeth AU - Berry, Gregory J. TI - Comparison of Four Molecular <em>In Vitro</em> Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens AID - 10.1101/2020.04.17.20069864 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.17.20069864 4099 - http://medrxiv.org/content/early/2020/04/22/2020.04.17.20069864.short 4100 - http://medrxiv.org/content/early/2020/04/22/2020.04.17.20069864.full AB - The novel human coronavirus SARS-CoV-2 was first discovered in the city of Wuhan, Hubei province, China, causing an outbreak of pneumonia in January 2020. As of April 10, 2020, the virus has rapidly disseminated to over 200 countries and territories, causing more than 1.6 million confirmed cases of COVID-19 and 97,000 deaths worldwide. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Further, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients. This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made.Competing Interest StatementGregory Berry has previously given education seminars for Hologic, Inc., and received an HonorariumFunding StatementWe would also like to thank Diasorin Molecular LLC. for providing the reagents used in this studyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnumbers from raw data are summarized in the manuscript to determine LoD, sensitivity, specificity, etc.